Proteomic Profiling of Small-Cell Lung Cancer: A Systematic Review

Simple Summary Our study centers on refining the diagnosis of small-cell lung cancer (SCLC), a unique subtype with distinct therapeutic implications compared to other lung cancers. Our primary goal is the identification of specific differentially expressed proteins in SCLC as opposed to healthy lung tissue. Additionally, we aim to discern the protein expression of SCLC from large cell neuroendocrine carcinoma (LCNEC), a closely related entity. This research has the potential to enhance our understanding of these intricate lung cancers, potentially transforming the landscape of detection and tailored treatment strategies. Abstract The accurate diagnosis of small-cell lung cancer (SCLC) is crucial, as treatment strategies differ from those of other lung cancers. This systematic review aims to identify proteins differentially expressed in SCLC compared to normal lung tissue, evaluating their potential utility in diagnosing and prognosing the disease. Additionally, the study identifies proteins differentially expressed between SCLC and large cell neuroendocrine carcinoma (LCNEC), aiming to discover biomarkers distinguishing between these two subtypes of neuroendocrine lung cancers. Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, a comprehensive search was conducted across PubMed/MEDLINE, Scopus, Embase, and Web of Science databases. Studies reporting proteomics information and confirming SCLC and/or LCNEC through histopathological and/or cytopathological examination were included, while review articles, non-original articles, and studies based on animal samples or cell lines were excluded. The initial search yielded 1705 articles, and after deduplication and screening, 16 articles were deemed eligible. These studies revealed 117 unique proteins significantly differentially expressed in SCLC compared to normal lung tissue, along with 37 unique proteins differentially expressed between SCLC and LCNEC. In conclusion, this review highlights the potential of proteomics technology in identifying novel biomarkers for diagnosing SCLC, predicting its prognosis, and distinguishing it from LCNEC.